Practical implementation of a modified continual reassessment method for dose-finding trials.
about
A modified toxicity probability interval method for dose-finding trials.Inducible apoptosis as a safety switch for adoptive cell therapyDimension of model parameter space and operating characteristics in adaptive dose-finding studies.Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated dose-finding trials.Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgeneHigh-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor ConsortiumDifferentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.Competing designs for phase I clinical trials: a review.Escalation with overdose control using time to toxicity for cancer phase I clinical trials.A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhageBayesian hybrid dose-finding design in phase I oncology clinical trials.Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantationA phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.Experimental designs for phase I and phase I/II dose-finding studies.Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma.Statistics in clinical research: Important considerationsBayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses.Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.Dose escalation methods in phase I cancer clinical trials.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.The changing landscape of phase I trials in oncology.Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.Robust EM Continual Reassessment Method in Oncology Dose FindingBayesian adaptive designs in single ascending dose trials in healthy volunteers.
P2860
Q27323581-288849AC-E773-4BEC-BB69-8ABD68DCC9B3Q29617710-17D6578B-9870-44F1-BA5F-C2DF439259F5Q30276967-A92CF1E2-CB97-4B21-B9FD-7AADF14ADBD4Q30623895-7A4604BD-5CA7-4A55-9C84-27C1649DB992Q33380081-F3233591-C891-4118-9304-A9DEE450DA20Q33393931-7C7C5329-807A-4A41-905B-51F050CBDDB1Q33781162-C60E8E3E-FDC8-4279-9726-7D7D8D835A0EQ33806054-38B80076-DCAE-446E-986E-5C57DF8C8B89Q34001009-01C52479-DF06-4A0D-BA6E-7500B83AE93DQ34292228-65218C0B-0132-4965-8CF7-D0D43CF27FDBQ34549158-74BB1DDC-2E62-4345-84E0-70682D05D78DQ34666866-2FD4D1D8-0A3E-4A27-BBC0-3F8FD05EAE2BQ34849945-BE45F6DA-C5A7-4A3D-840A-0D591158427CQ35129807-368BC339-19E9-47BF-96A9-CF2EB1763491Q35132415-DE77FCDF-CA42-4EB5-B87F-E30DA4358679Q35161796-28D8BB48-8950-482E-BABA-0C58E84EA109Q35449198-E37A826B-5E9B-4265-87E0-89D52CB471DCQ35776323-D4548936-1B95-4409-AED7-FCA446FC4667Q35784529-E44B370B-FE8B-467E-949F-04C90F63F7A2Q36031619-5B8CCB13-3688-42BC-AE21-4E9C58FA8B66Q36203084-A422A71B-D441-4C54-81E0-F9747DD64B22Q36376785-7BDDC4FE-1CE1-498E-AB43-6AACF36A1C7AQ36621961-FFC8E884-D803-4469-AA0C-C2F07DB95D37Q36908133-A478F278-DA86-4F5C-98D2-7610164F1446Q36926895-31F880A2-FA35-4A91-A0E1-0746D7C536A4Q36987761-FCE68F02-78AC-4510-B005-0614068C00F9Q37099409-A460699A-E109-4FD8-B66B-9C2500FDE7CCQ37125070-0A69535D-8AE1-411F-B370-73A5FB5F4052Q37198192-8F4BCC8C-B832-45B8-856A-C1FFADC32EE9Q37262792-4DCBE55C-3087-48DB-ADE1-E7A0F68361B9Q37523183-E2A447F3-A4CF-4A82-9517-157362E365A2Q37552670-0EB2ADF3-586B-4163-ADBF-B5B9CAA37C1BQ38629203-C235FA2F-B3BE-4419-B82E-FDD682623E65Q38790159-76984892-59DE-42DF-B797-39C7E6AB3A2DQ39620076-E37A58E6-13F1-4FCD-A2BF-A37DF3B6CD06Q40051812-CD74908D-B9E5-4493-BA07-35CF3B594C10Q40313777-FB930BD5-7C9C-4676-B697-DC8FD91307ADQ41151711-339EE9FE-81F5-49A2-BEE0-7DBAEF4FFD44Q41545765-200ECE0F-62AC-485B-933C-484FA7341E83Q41827277-F503E682-C993-41F9-B1CF-E5094C75D4EF
P2860
Practical implementation of a modified continual reassessment method for dose-finding trials.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Practical implementation of a ...... ethod for dose-finding trials.
@en
Practical implementation of a ...... ethod for dose-finding trials.
@nl
type
label
Practical implementation of a ...... ethod for dose-finding trials.
@en
Practical implementation of a ...... ethod for dose-finding trials.
@nl
prefLabel
Practical implementation of a ...... ethod for dose-finding trials.
@en
Practical implementation of a ...... ethod for dose-finding trials.
@nl
P2093
P356
P1476
Practical implementation of a ...... ethod for dose-finding trials.
@en
P2093
Grossman S
Piantadosi S
P2888
P304
P356
10.1007/S002800050763
P577
1998-01-01T00:00:00Z